Mechanistically, the expression of stromal PD-L1 might represent presence of restricted effector T cells in tumor microenvironment (TME), which was released by Pembrolizumab treatment, suggesting that stromal PD-L1 might be predictive for ICI response in patients with SCLC (28). Here, CD274 is linked to neoplasm.